{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Will be assessed in the bone marrow by flow cytometry estimated as the number of patients who have achieved MRD negative result at 10\\^-6 level of sensitivity at any time divided by the total number of evaluable patients. Exact 95% binomial confidence intervals for the true rate of MRD negative response will also be calculated.","groups":[{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Carfilzomib: Given IV\n\n\\>\n\n\\> Daratumumab: Given IV\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\n\n\\>\n\n\\> Selinexor: Given PO","id":"OG000","title":"Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)"}],"populationDescription":"Flow cytometry was not performed on collected samples and will never be performed due to early trial closure. Therefore, MRD is able to be assessed for 0 patients.","reportingStatus":"POSTED","timeFrame":"2 years","title":"MRD Negativity Rate at 10^-6 of Sensitivity","type":"SECONDARY"}